Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | ENERGIZE: chemo + nivo with/without linrod for bladder cancer

Guru Sonpavde • 15 Feb 2020
GU Cancers 2020
Bladder Cancer Genitourinary Cancer Antibodies Checkpoint Inhibitors Cisplatin Gemcitabine Linrodostat Nivolumab
ENERGIZE

Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, outlines ENERGIZE (NCT03661320), a Phase III trial investigating the efficacy of neoadjuvant chemotherapy in combination with nivolumab (nivo) with or without linrodostat (linrod) followed by postsurgery nivolumab or nivolumab with linrodostat in cisplatin-eligible patients with muscle-invasive bladder cancer. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Guru Sonpavde

1:36
Liquid biopsies and tumor-informed ctDNA profiling in metastatic urothelial carcinoma
Guru Sonpavde • 18 Feb 2022
1:40
Safety results from Phase 3b STRONG trial of durvalumab in patients with urinary tract carcinoma
Guru Sonpavde • 18 Feb 2022
1:06
Key trials in bladder cancer from ASCO GU 2022
Guru Sonpavde • 18 Feb 2022
1:34
Phase 2 trial of CV301 vaccine plus atezolizumab in advanced urothelial carcinoma
Guru Sonpavde • 18 Feb 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals